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Testicular Cancer and the 
Importance of Early Diagnosis
Serife Zehra Altunkurek
Abstract
Prevalence of cancers is growing rapidly in all parts of the world. Testicular 
cancer (TC) is one of the greatest threats to health among 15- to 34-year-old males. 
Since testicular cancer peaks in incidence among young men of reproductive age, 
it is an important type of cancer for men. Risk factors for testicular cancer include 
cryptorchidism (i.e., undescended testicles), family history, infertility, tobacco use, 
and white race. Therefore increasing awareness in this regard, a joint effort that 
encourages risk factors and preventive measures, must be shown. The treatments 
are very effective, which greatly increases the 5-year survival rate by approximately 
98%. Prevention is the best option to tackle TC. Secondary preventive measures, 
the most important testicular self-examination (TSE), are well known and are 
encouraged to them. TSE helps prevent the diagnosis of late-stage TSE. Because the 
treatment of testicular cancer detected early is often associated with very positive 
results, routine screening and monthly self-examination in young men have been 
suggested. Although testicular cancer is rare, it is very effective to treat symptoms 
when they are diagnosed by TSE. As with breast cancer, early detection of TC is best 
done through self-examination.
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1. Introduction
Cancer is the second leading cause of death globally and is responsible for 
an estimated 9.6 million deaths in 2018 [1]. A number of malignancies can be 
prevented through screening; an example is predominantly affecting males 
between 15 to 35 years of age and a relatively rare testicular malignancy that is a 
treatable cancer [2, 3]. However, TC incidence has risen worldwide in the past two 
decades [4]. Advances in the treatment of TC over the last 25 years have resulted 
in survival figures of 80–90%. Since TC peaks in incidence among young men of 
reproductive age, it is an important type of cancer for men [5]. Early diagnosis 
and treatment of TC is very important. TC is completely cured when detected at 
an early stage. Early diagnosis and 5-year survival rate is 99% [6–8]. Ninety to 
ninety-five percent of testicular tumors are caused by germinal tissue [9]. In this 
group, seminoma is the most common tumor with 40% [10]. The rate of cure with 
radiotherapy following orchiectomy in stage I seminoma is 99% [11]. Risk factors 
for TC include cryptorchidism (undescended testicles), abnormal development of 
testicles, adolescent and young adult age, family history, infertility, and white race 
[12–14]. Treatment is highly effective even when the diagnosis is made through 
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examination or because of symptoms [15]. As with breast cancer, early detection 
of TC is best done through self-examination [16]. Although routine screening and 
monthly self-examination in young men have been recommended, studies have 
not shown that they improve outcomes [17].
This chapter explains the epidemiology, etiology, stages, treatment of TC, and 
importance of early diagnosis for TC as well as TSE, as far as possible, with special 
considerations for adolescent and young adult populations.
2. Epidemiology
TC incidence is increasing worldwide, but the reasons for this increase 
are not fully documented [18]. There were a total of 36,747 cases of TC in the 
Scandinavian countries from 1960 to 2014 [19]. 9.4 affected individuals per 
100,000 males in Denmark had the highest incidence of TC for decades, but 
while the incidence rate stabilized in Denmark, the rate is now highest, 9.9 
affected individuals per 100,000 males in Norway [20, 21]. In the United States, 
TC is more common in white individuals (6.9 affected individuals per 100,000 
males) than in African Americans (1.2 affected individuals per 100,000 males) 
[18]. TC took first place with 24.8 percent of men in the 15-24 age group in 
Turkey [22]. An analysis from the International Agency for Research on Cancer 
indicates age-standardized rates of TC varied from less than 1/100,000 person 
14-35 years in Africa and Asia [23]. Worldwide, there are approximately 72,000 
cases and 9000 deaths per year attributable to TC [24]. TC death in the United 
States accounts for approximately 4% of the annual incidence [25]. There is a 
significant global variability in mortality rates that are largely inverse in inci-
dence rates. TC mortality is highest in low-income countries compared with 
higher-income countries [20]. Also, in spite of the highest incidences of this 
disease in Europe, North America and New Zealand account for only one-fifth 
of mortalities caused by TC [26]. About 50% of patients worldwide with TC are 
diagnosed with seminoma and the median ages at diagnosis 37 years [27].
2.1 Risk factors
The majority of TC (98%) had germ cell tumors; therefore, the terms testicular 
germ cell tumor and TC are often used interchangeably [28]. While most cancers 
occur in adulthood, the incidence of TC does not increase with age. The peak ages 
of occurrence are 25–29 years for non-seminomas and 35–39 years for seminomas 
[29]. The risk factors for TC are not well understood, but the risk factors most 
consistently associated with cryptorchidism, contralateral testicular tumor, a family 
history of TC, male factor ınfertility, and testicular microlithiasis [30–32].
Cryptorchidism, also referred to as maldescended testis, is the failure of descent 
of one or both of the testes into the scrotum and is a common clinical diagnosis 
in newborn boys and one of the strongest risk factors for infertility and testicular 
cancer [33–35]. Approximately 10% of all cases of testicular tumors occur in boys 
with a history of cryptorchidism [36]. In a study of patients with bilateral germ 
cell tumor, while 9.5% had cryptorchidism history, cryptorchidism was found 
in 2.2% of patients with unilateral tumors [37]. In addition, in a cohort study, 
cryptorchidism repair prior to puberty was associated with a doubling in risk of 
testicular cancer; postponement of the repair after the age of 12 showed that the 
risk increased fivefold [38].
TC is associated with a family history link as well [33–35]. Men, who have a first-
degree relative with testicular cancer, have a reasonably increased risk [39]. Patients 
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with a history of personal testicular cancer have a 12-fold higher risk of developing 
TC than the general population [40]. Family cancer studies have shown that sons 
whose fathers have TC have four times the risk of testicular cancer and brothers of 
patients with TC have eight times the risk of having testicular cancer [41]. Family 
history of this relationship is white men are more likely than black men to develop 
TC [15]. In a study with a large population, contralateral testicular cancer explained 
that a man younger than age of 30 with testicular seminoma has a 3.1% risk of 
developing a TC [42].
TC has increased in the last 30 years, while in Western countries there has 
been a decrease in semen quality and fertility [41]. Men with infertility have an 
increased risk of TC, with an incidence ratio of 1.6–2.8 [43]. The cohort study, 
based on more than 22,000 men undergoing evaluation for infertility, examined 
an association between infertility and the development of testicular cancer [44]. 
Other risk factors in TC are vasectomy, scrotal trauma, inguinal hernia, diet, 
smoking, the gene, environment (such as heavy metals exposure and endocrine 
disruptors), and hormones [45–50].
3. Diagnosing testicular cancer
TC is often seen as a painless mass in the testis, but in many patients there is 
a widespread pain, swelling, or stiffness in the scrotum [51]. Testicular masses 
appear more often on the right side [8]. Acute testicular pain is less widespread and 
is reasoned by swift expansion of the testis owing to intratumor hemorrhage or 
infarction caused by swift tumor growth [39]. Men often notice a history of testicu-
lar trauma, though accidental trauma is probably liable for leading the testicular 
mass to the men’ s attention, firstly. Men may complain of unclear scrotal pain or 
heaviness [39]. Testicular masses can be urgently evaluated by physical exam and 
bilateral testicular ultrasound [6]. Physical examination may be determinative but 
is sometimes vague in differentiating a malignancy from nonmalignant testicular 
masses [52].
The physician should carefully examine the testes, noting their notional size 
and density and palpating for any testicular masses [39]. Any doubtful symptoms 
should give rise to adjuvant studies [53]. Table 1 shows the signs and symptoms of 
TC [15].
Discomfort Metastases*
Dull ache in the scrotum or abdomen Gastrointestinal symptoms
Acute pain in the testicle or scrotum Gynecomastia
Scrotal heaviness Lumbar back pain
Mass effect Neck mass
Firmness of the testicle Respiratory symptoms (e.g., cough, hemoptysis, dyspnea)
Infertility
Intratesticular mass
Painless swelling and redness
*About 5% of patients with testicular cancer have symptoms of metastases.
Information from Ref. [15].
Table 1. 
Signs and symptoms of testicular cancer.
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In men showing with testicular mass, unexplained scrotal pain or signs, 
ultrasonography should be regarded an appendage of the physical examination 
due to being broadly existing, cheap, and noninvasive [54]. After Physical exami-
nation, for revealing a mass in the testicle and the first radiological evaluation 
was Ultrasonography [55]. First of all intratesticular mass or the extratesticular 
location is examined. The intratesticular masses tend to be malignant, and the 
extratesticular masses tend to be benign. The nature of the detected masses (solid 
or cystic) is determined by Ultrasonografi (US). Solid masses suggest more malig-
nancy, whereas cystic masses are often benign, such as rete testis ectasia, simple 
cyst, and tunica albuginea cyst [55].
Tumor markers are also an important part of the diagnostic workup. Beta-
human chorionic gonadotropin (Bhcg), alpha-fetoprotein (AFP), and lactate 
dehydrogenase (LDH) levels are checked for the diagnosis of testicular tumors [56]. 
At the same time, these marker levels should be acquired after orchiectomy and to 
monitor chemotherapy treatment [39]. At the beginning of cancer, levels of these 
markers tend to be in the normal level. LDH levels are often elevated metastatic 
testicular cancer [15].
A biopsy can damage the testicles and spread the cancer into scrotum, so biopsy 
is not recommended [57]. But if suspected of having testicular tumor, one should 
undergo a radical inguinal orchiectomy for pathologic evaluation [39].
4. The stages of testicular cancer
Testicular cancers are classified as seminomas or non-seminomas. The semino-
mas are most common tumor with 40%. Three histological subtypes are defined. 
The most common type is classical type seminoma with 85%. Firstly, it makes lenfoj 
metastasis. It responds to radiotherapy and chemotherapy very well [58]. Non-
seminoma tumors account for 4% of all testicular tumors. Leydig cell tumors are 
the most common and this tumor constitutes 1–2% of all testicular tumors. It has a 
benign character in children but it is 10% malignant in adults [59].
Staging in TC is useful for determining prognosis and treatment. Patients are 
classified as Stage I (limited to the testis), Stage II (lymph node involvement), and 
Stage III (metastasis to visceral organs) [60] (Table 2). Among the important fac-
tors to be considered when staging are the degree of metastasis, elevation of tumor 
markers, and histology (seminoma or nonseminoma).
Stage I The tumor is in the testis. No evidence of metastasis was found in any of the testis
Stage IM After orchiectomy tumor markers in height is observed
Stage II Retroperitoneal lymphadenopathy is present
 IIA Lymphadenopathy <2 cm across
 IIB = 2–5 cm across
 IIC >5 cm across
Stage III Supradiaphragmatic lymphadenopathies are present
Stage IV Organ metastasis/hematogenous spread
Information from Refs. [61, 62].
Table 2. 
Classifications of testicular cancer staging.
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5. Treating testicular cancer
The primary treatment for testicular tumors is radical inguinal orchiectomy 
involving the removal of the testis and spermatic cord. After orchiectomy, the type 
of tumor (seminoma or nonseminoma tumor) and its stage are determined by 
microscopic diagnosis for further treatment [63]. Treatment options include obser-
vation, dissection of the retroperitoneal lymph node, radiation, and chemotherapy 
[15]. Treatment options for specific stages of disease are summarized in Table 3. To 
determine the success and continuity of treatment, evaluation is made by looking at 
the changes in serum tumor markers [15].
6. Fertility issue
Studies have shown that fertility decreased after treatment in TC patients. In 
addition, treatment with chemotherapy and radiotherapy was reported to cause 
significant gonadal damage in men [64, 65].
In one study, half of the patients wanted to have children after TC treatment. 
However, according to the results of the study, fertility rate was lower after treat-
ment than before treatment [66]. In the other study after treating for TC, 13 percent 
of patients developed hypogonadism [67]. Therefore, since the treatments to be 
applied to TC patients have a negative effect on fertility, solutions such as sperm 
banking, testicular tissue freezing, or removal of testicular sperm should be dis-
cussed with the patient before starting the treatment [68, 69].
Stage Seminoma Nonseminoma
I Usually low-dose radiotherapy as a 
preservative
Retroperitoneal lymph node dissection or monthly 
follow-up observations
IB: Take into two courses of chemotherapy
IS: The whole-dose chemotherapy if serum tumor 
marker levels do not drop swiftly after surgery
II IIA: Radiation therapy of the local lymph 
nodes
IIB or IIC: Three courses of three-drug 
chemotherapy
IIA: Retroperitoneal lymph node dissection, 
followed by monthly monitoring and frequent lab 
tests or observation, was made by two courses of 
chemotherapy, two drugs
IIB or IIC: If computed tomography still indicates 
lymph nodes, three or four courses of three-drug 
chemotherapy followed by retroperitoneal lymph 
node dissection
III Three-drug chemotherapy: If there is no 
answer, think of the clinical tests of other 
chemotherapy drugs in combination
Have brain metastasis: Treat with brain 
radiation or operating disposal
Three-drug chemotherapy: operating disposal of 
permanent tumors
High serum tumor marker levels: These patients 
often do not respond to usual chemotherapy; 
therefore, more aggressive clinical trials may be 
considered
High serum tumor marker levels: These 
patients frequently do not answer to normal 
chemotherapy; hence, more aggressive clinical 
trials can be thought
Information from Ref. [15].
Table 3. 
Treatment types for the stages of testicular cancer.
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7. The importance of early detection of TC and TSE
The aim of any cancer screening program is to diagnose the disease at an earlier 
and more easily treatable stage by improving disease-specific survival and minimiz-
ing treatment morbidity [70].
As with all cancer cases, when testicular cancer is diagnosed in early stages, the 
rate of treatment for TC is approximately 96%, significantly affecting survival [71]. 
Unfortunately, more than 50% of cases are diagnosed after the disease has spread 
to the primary site, and men must be persuaded to avoid medical treatment as soon 
as a mass is detected [72]. Once the cancer has expanded over the local nodes (Stage 
III), the survival rate decreases extremely. This is because approximately every 
10–30 days, the tumor doubling times were fast. Therefore, early diagnosis equates 
with a better long-term overall prognosis [6]. Obviously, for testicular cancer, a 
potentially lethal disease, early detection and early treatment are very important [6]. 
Rapid diagnosis of these neoplasms provides the opportunity to treat these patients 
at the earliest stage of the disease and thus minimize long-term morbidity [70].
Despite the importance of early diagnosis, invisible dangers are common in early 
and definitive diagnosis of testicular tumors. There are many studies based on delay 
in the diagnosis of testicular cancer [73–75]. In a comprehensive study on delayed 
diagnosis (DD) in testicular cancer, DD confirmed that it had a significant effect on 
survival in TC patients receiving modern treatments, including chemotherapy [76]. 
On the other hand, Nikzas et al. found no effect on survival in delay between 1980 
and 1987 in 232 patients studied in Great Britain [77].
Both patients and health professionals can contribute to delay in diagnosis. 
Patient-induced delays due to unawareness, embarrassment, fear of cancer, or fear 
of emasculation are accepted [75, 78–80]. The results of literature reviews suggest 
that approximately 20–30% of cancer patients delay seeking help for more than 
3 months after having experienced possible symptoms of cancer [81].
TC affects young and generally healthy males who do not accept the threat of 
deadly disease. Moreover, that testicular cancer requires loss of external genitals dur-
ing a time in the man’s life when sexuality is very important is additionally stressful 
[70]. The physician-mediated delay is most often the misdiagnosis of a testicular 
tumor as an infection. Unluckily for clinicians, classic painless testicular mass of 
patients ultimately diagnosed with TC is only half the resulting symptoms [82].
For early diagnosis several organizations, including the American Cancer 
Society and American Urological Association, recommend that physicians include 
testicular examination as part of routine control [83].It is also recommended that 
primary healthcare professionals teach and encourage TSE to males between the 
ages of 15 and 35 years [84]. At the same time, the American Cancer Society recom-
mends to men, especially who at high risk for TC, TSE as an effective and cost-free 
method [71]. Studies have shown that men at risk for TC are not educated and do 
not know how to perform TSE [6]. Moreover, many studies reported that close to all 
men of the risk group (adult men below age 35) had never performed TSE and very 
few knew that men who were in the 18- to 50-year-old age group should perform 
TSE every month [16, 85].
TSE is the cheapest and easiest method for screening firstly taught by the nurses 
or physicians to the man. The man is taught to perform the TSE when the scrotum 
is soft and relaxed, usually after a shower. In addition, TSE is recommended to be 
done at least once a month starting at the onset of puberty [17]. TSE teaching begins 
when the man becomes familiar with the major structures of the testis, scrotum, 
testicle, and epididymis [86]. After being familiar with the normal tissue and 
structures of the testes, the man is better readied to identify normal physiological 
structures. Any suspicious masses are notified to a healthcare professional as soon 
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as possible [86]. However, the role of TSE in screening of testicular cancer is still a 
matter of debate. In testicular cancer, regular TSE to prove the relationship between 
life and life US Preventive Services Task Force Some organizations such as the 
Canadian Task Force are out of the ordinary they do not recommend regular TSE 
because they can cause anxiety and unnecessary doctor visits [87, 88]. However, 
self-testis may be useful in increasing the incidence of testicular cancer and in 
early diagnosis because of the very low number of men participating in preven-
tive healthcare [89]. TSE is a convenient method to detect testicular cancer and 
contribute to healthier lifestyles for men at risk [71]. Furthermore, TSE, potentially 
positive, can produce sustainable health behavior choices [90].
8. Conclusions
In conclusion, studies have shown that the incidence of TC is increasing, espe-
cially in developed countries, where it is the most commonly diagnosed malignancy 
in young men. For this reason, young men should be encouraged to be aware of 
early detection of TC, to raise awareness and to apply to the health institution. In 
general, with rates of treatment above 95% (80% for metastatic disease), TC is 
considered to be a curable cancer when diagnosed early. At the same time, contrary 
to the supposition of men, treatment of TC is generally a type of cancer that does 
not cause sexual problems and does not affect fertility, and men’s masculinity is 
maintained unless both testicles are affected for a long time. The men that will be 
given TSE training may need to be present as educators because some men find the 
discussion of their testicles embarrassing. Furthermore, teaching young men to 
conduct TSE may result in these men taking increased responsibility for their own 
healthcare. When men are aware of what is normal for themselves, they are more 
likely to consult in the absence of false assurances from the absence of a lack of 
precariousness when they detect any abnormal condition. It is equally important to 
tell men that the diagnosis of testicular cancer is not death and the rate of treatment 
is excellent. Efforts should be made to make men aware that there may be a disease 
in their testicles even when there is no pain.
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